BioCryst to Showcase Expanded HAE Data at AAAAI 2026, Highlighting Navenibart's Long-Term Potential
Event summary
- BioCryst will present nine abstracts at the 2026 AAAAI Annual Meeting, including six on ORLADEYO and three on navenibart.
- Late-breaking data highlights sustained HAE attack suppression with navenibart administered every 3 or 6 months.
- ORLADEYO data includes real-world outcomes and pediatric efficacy in children aged 2 to less than 12 years.
- Event runs February 27–March 2, 2026, in Philadelphia.
The big picture
BioCryst's presentation at AAAAI 2026 underscores its strategy to diversify its HAE portfolio with both oral and injectable therapies. The focus on long-acting prophylaxis with navenibart aligns with broader industry trends toward patient-centric, convenient dosing regimens. Success here could solidify BioCryst's leadership in HAE treatment, but competition and regulatory hurdles remain critical variables.
What we're watching
- Regulatory Pathway
- Whether navenibart's long-term efficacy data accelerates its approval timeline as a best-in-class prophylactic for HAE.
- Market Differentiation
- How BioCryst positions ORLADEYO and navenibart against existing HAE treatments, emphasizing convenience and sustained efficacy.
- Commercial Strategy
- The pace at which BioCryst expands ORLADEYO's pediatric indication and navigates competitive dynamics in the HAE space.
Related topics